One man's gain is often another's loss. When it comes to competing thematic plays in the corporate world, however, the magnitude of ensuing gains and losses can be truly mind-boggling. With analysts estimating over $100 billion in annual US sales for the revolutionary GLP-1 anti-obesity drugs from the likes of Novo Nordisk and Eli Lilly […]
Read full article at https://wccftech.com/here-is-why-mcdonalds-will-be-just-fine-even-as-anti-obesity-glp-1-drugs-from-eli-lilly-and-novo-nordisk-decimate-demand-in-the-west/
WccftechContinue reading/original-link]